Expansion of Cannabis Cultivation Market is fueled by the legalization of cannabis for treating chronic ailments
From 2020 to 2027, the worldwide cannabis cultivation market is predicted to increase at a compound annual growth rate (CAGR) of 14.3 percent. The market's expansion is being fueled by rising legalisation and the use of cannabis for the treatment of chronic ailments. Furthermore, the liberalisation of cannabis growing legislation, particularly for hemp cultivation, by several countries due to its low THC concentration, is accelerating its acceptance. In addition, the legalization of marijuana in several countries and its growing use for medical purposes are pushing the cannabis production business. In Germany, for example, there was a large increase in the number of patients following the legalisation of marijuana for medical purposes in 2017. According to a 2019 analysis provided by Bank of Montreal, the number of patients in Germany jumped from 1,000 to 30,000-50,000 after medicinal marijuana was legalised.
Furthermore, demand for hemp extracts is rapidly increasing, as many developed countries have legalised the cultivation and processing of hemp after recognising the high levels of CBD present in it, resulting in increased demand for hemp extracts in a variety of industries, including pharmaceuticals, cosmetics, nutraceuticals, and food and beverage. Hemp is grown in more than 40 nations as an agricultural crop. It's a cannabis Sativa strain from the cannabis genus, with THC levels as low as 0.3 percent. China, Canada, France, Chile, South Korea, Ecuador, Croatia, the Czech Republic, Mongolia, Romania, and Russia are among the world's leading hemp producers.
Although medical cannabis has been approved in a number of nations, it has only been legalised for certain reasons in others. In Croatia, for example, medical marijuana is authorised for people with AIDS, cancer, multiple sclerosis, and epilepsyFurthermore, medical marijuana can only be used for severe muscle spasms, chemotherapy-induced nausea and vomiting, epilepsy with severe seizures, and palliative care in Queensland, Australia. This narrow breadth of use in a number of countries is anticipated to stifle market expansion and cultivation.
Furthermore, the strong demand for medical cannabis has caused a supply chain bottleneck in a number of countries. This is owing to a significant growth in demand as well as cultivation restrictions in several countries. For example, attractive areas like Germany are experiencing a lack of medicinal cannabis, forcing patients to pay exorbitant costs. According to the Bank of Montreal, patients in Germany are paying higher average prices than patients in Canada in 2019, which has slowed the expansion of the Cannabis Cultivation Market.
Comments
Post a Comment